X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Novartis will have global exclusive rights to develop and commercialize CKD-510, a small molecule histone deacetylase 6 (HDAC6) inhibitor developed by CKD Pharm worldwide, excluding Korea.
Lead Product(s): CKD-510
Therapeutic Area: Genetic Disease Product Name: CKD-510
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,305.0 million Upfront Cash: $80.0 million
Deal Type: Licensing Agreement November 07, 2023
Details:
Under the agreement, Aclipse gains worldwide rights to develop CKD’s M107 (lobeglitazone), an oral, small molecule, for gastroparesis and additional indications.
Lead Product(s): Lobeglitazone
Therapeutic Area: Gastroenterology Product Name: M107
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aclipse Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 14, 2023
Details:
Under the terms of the licensing agreement, Synaffix will provide access to proprietary Antibody-Drug Conjugate technologies to CKD Pharm, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Synaffix
Deal Size: $132.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 06, 2023
Details:
The drug, Nafabeltan, will be administered to patients as part of the Australian government-led clinical study to find a COVID-19 treatment. The drug is currently used as a blood anticoagulant and acute pancreatitis treatment.
Lead Product(s): Nafamostat
Therapeutic Area: Infections and Infectious Diseases Product Name: Nafabeltan
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
Russia’s Drug Ministry approved of its clinical phase two trial design targeting some 100 seriously afflicted COVID-19 pneumonic patients there. The patients will be administered nafamostat for 10 days.
Lead Product(s): Nafamostat
Therapeutic Area: Infections and Infectious Diseases Product Name: Nafabeltan
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
Chong Kun Dang Pharmaceuticals (CKD) of South Korea, has licensed the distribution rights to Namodenoson in South Korea for the treatment of liver cancer and NASH.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Can-Fite BioPharma
Deal Size: $8.0 million Upfront Cash: $6.0 million
Deal Type: Licensing Agreement February 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
